Pulmonary Fibrosis News and Research

RSS

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF.

5 Aug 2014

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms.

30 Jul 2014

Four major health institutions jointly receive $7 million for health data research network

Four major health institutions, including Penn State College of Medicine, have jointly received nearly $7 million to develop and expand a health data research network.

30 Jul 2014

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows.

23 Jul 2014

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF).

17 Jul 2014

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.

19 Jun 2014

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.

9 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Patient registry to help clinicians identify, manage people who have progressive lung disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

5 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Researchers find link between aging and chemicals in environment

Why are some 75-year-olds downright spry while others can barely get around? Part of the explanation, say researchers writing in the Cell Press journal Trends in Molecular Medicine on May 28, is differences from one person to the next in exposure to harmful substances in the environment, chemicals such as benzene, cigarette smoke, and even stress.

29 May 2014

X-ray dark-field radiography creates higher resolution images of lung disease

Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.

27 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

First Edition: May 19, 2014

Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges.

19 May 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

PFF Patient Communication Center: The destination for latest disease education information

The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone.

16 May 2014

Pulmonary Fibrosis News and Research

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Four major health institutions jointly receive $7 million for health data research network

Combined risk score enhances radiation pneumonitis prediction

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Gene variants that lead to longer telomeres boost brain cancer risk

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Patient registry to help clinicians identify, manage people who have progressive lung disease

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Amgen presents extended analysis of PEAK study data at ASCO

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Researchers find link between aging and chemicals in environment

X-ray dark-field radiography creates higher resolution images of lung disease

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

First Edition: May 19, 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

PFF Patient Communication Center: The destination for latest disease education information

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News